Impact of guidelines on outcome: The evidence

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 2, 2009, Pages 172-178

  Martínez, Raquel ^a,b,c   Reyes, Soledad ^a   Lorenzo, Ma José ^a   Menéndez, Rosario ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cost effectiveness; Mortality; Pathway; Stability; Treatment failure

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; CAUSE OF DEATH; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MEDICAL SOCIETY; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SPAIN; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 63149187230     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1202936     Document Type: Review

References (43)

1. Minino AM, Smith BL. Deaths: preliminary data for 2000. Natl Vital Stat Rep 2001;49:1-40
2. European Respiratory Society. Pneumonia. In: Loddenkemper R, ed. European Lung White Book. Loussane; 2003:55-65
3. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-837
4. Monge V, San-Martin VM, Gonzalez A. The burden of community-acquired pneumonia in Spain. Eur J Public Health 2001;11:362-364
5. Alfageme I, Aspa J, Bello S, et al. Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2005;41:272-289
6. Mandell LA, Wunderink RG, Anzueto A, et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia. Clin Infect Dis 2007;44:S27-S72
7. Woodhead M. Community-acquired pneumonia guidelines: an international comparison: a view from Europe. Chest 1998;113(3 Suppl):183S-187S
8. Barlow GD, Lamping DL, Davey PG, Nathwani D. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. Lancet Infect Dis 2003;3:476-488
9. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-644
10. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006;130:11-15
11. Rhew DC. Quality indicators for the management of pneumonia in vulnerable elders. Ann Intern Med 2001;135:736-743
12. Barlow G, Nathwani D, Williams F, et al. Reducing door-toantibiotic time in community-acquired pneumonia: controlled before-and-after evaluation and cost-effectiveness analysis. Thorax 2007;62:67-74
13. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA 1999;282:1458-1465
14. Halm EA, Atlas SJ, Borowsky LH, et al. Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. Arch Intern Med 2000;160:98-104
15. Schouten JA, Hulscher ME, Kullberg BJ, et al. Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors. J Antimicrob Chemother 2005;56:575-582
16. Rello J, Lorente C, Bodi M, Diaz E, Ricart M, Kollef MH. Why do physicians not follow evidence-based guidelines for preventing ventilator-associated pneumonia? A survey based on the opinions of an international panel of intensivists Chest 2002;122:656-661
17. Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect 2008;14(Suppl 3):15-21
18. Bjerre LM, Verheij TJ, Kochen MM. Antibiotics for community acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2004;(2):CD002109
19. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997;278:32-39
20. Suchyta MR, Dean NC, Narus S, Hadlock CJ. Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am J Med 2001;110:306-309
21. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001;110:451-457
22. Menéndez R, Torres A, Zalacain R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005;172:757-762
23. Dean NC, Bateman KA, Donnelly SM, Silver MP, Snow GL, Hale D. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 2006;130:794-799
24. Capelastegui A, Espana PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004;39:955-963
25. Menéndez R, Ferrando D, Valles JM, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 2002;122:612-617
26. Blasi F, Iori I, Bulfoni A, Corrao S, Costantino S, Legnani D. Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur Respir J 2008;32:902-910
27. Mortensen EM, Restrepo MI, Anzueto A, Pugh JA. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med 2006;119:859-864
28. Bodi M, Rodriguez A, Sole-Violan J, et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005;41:1709-1716
29. Shorr AF, Bodi M, Rodriguez A, Sole-Violan J, Garnacho-Montero J, Rello J. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest 2006;130:93-100
30. Reyes S, Martinez R, Valles JM, Cases E, Menéndez R. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J 2008;31:1061-1067
31. Menéndez R, Ferrando D, Valles JM, Martinez E, Perpina M. Initial risk class and length of hospital stay in community-acquired pneumonia. Eur Respir J 2001;18:151-156
32. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000;34:446-452
33. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999;159:2576-2580
34. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-2572
35. Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-1093
36. Menéndez R, Torres A, Rodriguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-1790
37. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-755
38. Meehan TP, Weingarten SR, Holmboe ES, et al. A statewide initiative to improve the care of hospitalized pneumonia patients: The Connecticut Pneumonia Pathway Project. Am J Med 2001;111:203-210
39. Frei CR, Restrepo MI, Mortensen EM, Burgess DS. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006;119:865-871
40. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med 2002;162:682-688
41. Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics 2004;22:751-757
42. Menéndez R, Reyes S, Martinez R, de la Cuadra P, Manuel Valles J, Vallterra J. Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia. Eur Respir J 2007;29:751-756
43. Gora-Harper ML, Rapp RP, Finney JP. Development of a best-practice model at a university hospital to increase efficiency in the management of patients with community-acquired pneumonia. Am J Health Syst Pharm 2000;57(Suppl 3):S6-S9